SK Biopharmaceuticals to In-License Epilepsy Drug Candidate 'Opakalim'

PartnershipOpakalimPositive

AI Analysis

Summary

SK Biopharmaceuticals announced an in-licensing agreement for Opakalim, a near-commercial epilepsy drug candidate, with potential upfront and milestone payments up to $795M. The company targets U.S. commercial launch as early as 2029.

Outcome Details

In-licensing agreement for Kv7 platform candidate with upfront and milestone payments up to $795M

Importance:7/10

Sentiment:

0.70

in-licensingpartnershipepilepsycommercial launchkv7 platform

Related Companies

$SKBP

Read the original article

Published by PR Newswire Biotech on August 26, 2026 9:29 AM

Read Original